Biotechnology

Terumo Blood and Cell Technologies (Terumo BCT) and the Sanquin Blood Supply Foundation, the Netherlands national blood supply authority, have signed a 10-year agreement to implement Lakewood-based Terumo BCT’s Reveos Automated Blood Processing System across Sanquin’s blood processing facilities. Sanquin, known for its pioneering buffy coat process for producing blood components, will transition to the…more

Aclarion Inc. announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. The randomized controlled trial is studying 202 patients with low back pain lasting more than one year and will compare outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation. Nociscan was selected for use in the…more

Aclarion Inc. announced the launch of a program aimed at developing a statewide network of providers in New Jersey to utilize its AI technology, Nociscan, for the personal injury and workers compensation sectors. Dr. Justin Kubeck, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, N.J., will lead this initiative to…more

Westminster-based ARCA Biopharma Inc. (NASDAQ: ABIO) announced the completion of its merger with Oruka Therapeutics Inc. The merger follows ARCA’s successful receipt of stockholder approval for all related proposals at a special meeting on Aug. 22, 2024. The combined company will operate as “Oruka Therapeutics Inc.”, with its common stock to be traded on Nasdaq…more

Aclarion Inc. announced the expansion of its multi-center Clinical Utility and Economic (CLUE) Trial to New Jersey. Dr. Justin Kubeck, an orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms River, will initiate the trial in the state. The CLUE Trial aims to assess how often Nociscan’s AI-generated data alters the treatment…more

Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology firm, has announced the launch of the multi-center Clinical Utility and Economic (CLUE) Trial. The trial aims to quantify the frequency with which surgeons alter their original treatment plans after receiving data from Aclarion’s proprietary Nociscan technology. In the CLUE Trial, surgeons will determine their…more

ARCA Biopharma Inc. (Nasdaq: ABIO), a Westminster company known for its focus on genetically targeted therapies for cardiovascular diseases, has announced a significant update regarding its corporate strategy and planned merger with Oruka Therapeutics Inc. As part of the merger, ARCA plans to divest its legacy technology and intellectual property, including assets related to Gencaro…more

Aclarion Inc., a Broomfield-based health care technology firm, has announced the extension of its commercial agreement with the prestigious London Clinic. This contract expansion signifies increased payment for each Nociscan use, efforts to secure payer coverage decisions from top private health insurers, and strategies to enhance access to Nociscan within the greater London market. Aclarion,…more

Global ingredient manufacturer Kemin Industries has acquired Littleton-based Archangel Inc., an antimicrobial producer for biofuel production. Archangel Inc., founded in 2015 by Allen Ziegler, develops advanced bacterial control solutions for the biofuels industry. Post-acquisition, Ziegler will join Kemin as a Principal Sales Manager for the Kemin Bio Solutions business unit. “This acquisition is a significant…more

ARCA Biopharma, a Westminster-based company specializing in targeted therapies for cardiovascular diseases, has reported the departure of their President and CEO, Dr. Michael Bristow, and appointment of Thomas Keuer as the new President. This transition took effect on April 3, 2024, when ARCA and Dr. Bristow mutually decided to end his tenure as both an…more